| Year |
Citation |
Score |
| 2022 |
Jacobson JM, Zahrieh D, Strand CA, Cruz-Correa M, Pungpapong S, Roberts LR, Mandrekar SJ, Rodriguez LM, Boyer J, Marrero I, Kraynyak KA, Morrow MP, Sylvester AJ, Pawlicki JM, Gillespie E, et al. Phase I Trial of a Therapeutic DNA Vaccine for Preventing Hepatocellular Carcinoma from Chronic Hepatitis C Virus (HCV) Infection. Cancer Prevention Research (Philadelphia, Pa.). OF1-OF11. PMID 36534786 DOI: 10.1158/1940-6207.CAPR-22-0217 |
0.512 |
|
| 2022 |
Jacobson JM, Zahrieh D, Strand CA, Cruz-Correa M, Pungpapong S, Roberts LR, Mandrekar SJ, Rodriguez LM, Boyer J, Marrero I, Kraynyak KA, Morrow MP, Sylvester AJ, Pawlicki JM, Gillespie E, et al. Phase I Trial of a Therapeutic DNA Vaccine for Preventing Hepatocellular Carcinoma from Chronic Hepatitis C Virus (HCV) Infection. Cancer Prevention Research (Philadelphia, Pa.). PMID 36474313 DOI: 10.1158/1940-6207.CAPR-22-0217 |
0.34 |
|
| 2022 |
Kraynyak KA, Blackwood E, Agnes J, Tebas P, Giffear M, Amante D, Reuschel EL, Purwar M, Christensen-Quick A, Liu N, Andrade VM, Diehl MC, Wani S, Lupicka M, Sylvester A, et al. SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial. The Journal of Infectious Diseases. PMID 35079784 DOI: 10.1093/infdis/jiac016 |
0.642 |
|
| 2021 |
Vonderheide RH, Kraynyak KA, Shields AF, McRee AJ, Johnson JM, Sun W, Chintakuntlawar AV, Pawlicki J, Sylvester AJ, McMullan T, Samuels R, Kim JJ, Weiner D, Boyer JD, Morrow MP, et al. Phase 1 study of safety, tolerability and immunogenicity of the human telomerase (hTERT)-encoded DNA plasmids INO-1400 and INO-1401 with or without IL-12 DNA plasmid INO-9012 in adult patients with solid tumors. Journal For Immunotherapy of Cancer. 9. PMID 34230114 DOI: 10.1136/jitc-2021-003019 |
0.493 |
|
| 2020 |
Tebas P, Yang S, Boyer JD, Reuschel EL, Patel A, Christensen-Quick A, Andrade VM, Morrow MP, Kraynyak K, Agnes J, Purwar M, Sylvester A, Gillespie E, Maricic I, Zaidi FI, et al. Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial. Eclinicalmedicine. 100689. PMID 33392485 DOI: 10.1016/j.eclinm.2020.100689 |
0.603 |
|
| 2020 |
Shore ND, Morrow MP, McMullan T, Kraynyak KA, Sylvester A, Bhatt K, Cheung J, Boyer JD, Liu L, Sacchetta B, Rosencranz S, Heath EI, Nordquist L, Cheng HH, Tagawa ST, et al. CD8 T Cells Impact Rising PSA in Biochemically Relapsed Cancer Patients Using Immunotherapy Targeting Tumor-Associated Antigens. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 32208168 DOI: 10.1016/J.Ymthe.2020.02.018 |
0.513 |
|
| 2020 |
Hasan Y, Furtado L, Tergas A, Lee N, Brooks R, McCall A, Golden D, Jolly S, Fleming G, Morrow M, Kraynyak K, Sylvester A, Arif F, Levin M, Schwartz D, et al. A Phase I trial assessing the safety and tolerability of a therapeutic DNA vaccination against HPV16 and HPV18 E6/E7 oncogenes after chemoradiation for cervical cancer. International Journal of Radiation Oncology, Biology, Physics. PMID 32151670 DOI: 10.1016/J.Ijrobp.2020.02.031 |
0.462 |
|
| 2020 |
Aggarwal C, Cohen RB, Morrow MP, Kraynyak KA, Sylvester AJ, Cheung J, Dickerson K, Schulten V, Knoblock D, Gillespie E, Bauml JM, Yan J, Diehl M, Boyer J, Dallas M, et al. Immune Therapy Targeting E6/E7 Oncogenes of Human Paillomavirus Type 6 (HPV-6) Reduces or Eliminates the Need for Surgical Intervention in the Treatment of HPV-6 Associated Recurrent Respiratory Papillomatosis. Vaccines. 8. PMID 32013270 DOI: 10.3390/Vaccines8010056 |
0.568 |
|
| 2020 |
Reardon DA, Brem S, Desai AS, Bagley SJ, Kurz SC, De La Fuente MI, Nagpal S, Welch MR, Hormigo A, Carroll N, Bartra SK, Campbell P, Bhatt K, Lowy I, Boyer J, ... Kraynyak K, et al. INO-5401 and INO-9012 delivered intramuscularly (IM) with electroporation (EP) in combination with cemiplimab (REGN2810) in newly diagnosed glioblastoma (GBM): Interim results. Journal of Clinical Oncology. 38: 2514-2514. DOI: 10.1200/Jco.2020.38.15_Suppl.2514 |
0.532 |
|
| 2020 |
Aggarwal C, Cohen RB, Morrow MP, Kraynyak KA, Cheung J, Dickerson K, Schulten V, Knoblock D, Gillespie E, Bauml JM, Diehl M, Boyer J, Dallas M, Weiner DB, Skolnik JM. Abstract CT126: A synthetic DNA plasmid encoding HPV6 E6 and E7 proteins in patients with HPV6-associated aerodigestive lesions Tumor Biology. DOI: 10.1158/1538-7445.Am2020-Ct126 |
0.513 |
|
| 2020 |
Skolnik J, Reardon D, Brem S, Desai A, Bagley S, Kurz S, Fuente Mdl, Nagpal S, Welch M, Sacchetta B, Bartra S, Bredlau A, Lowy I, Kraynyak K, Morrow M, et al. P858 An open-label, multi-center trial of INO-5401 and INO-9012 delivered by electroporation (EP) in combination with cemiplimab in subjects with newly-diagnosed glioblastoma (GBM) Journal For Immunotherapy of Cancer. 8: A8.1-A8. DOI: 10.1136/Lba2019.12 |
0.394 |
|
| 2019 |
Bernstein DI, Morello CS, Cardin RD, Bravo FJ, Kraynyak KA, Spector DH. A vaccine containing highly purified virus particles in adjuvant provides high level protection against genital infection and disease in guinea pigs challenged intravaginally with homologous and heterologous strains of herpes simplex virus type 2. Vaccine. PMID 31611098 DOI: 10.1016/J.Vaccine.2019.09.090 |
0.396 |
|
| 2019 |
Tebas P, Kraynyak KA, Patel A, Maslow JN, Morrow MP, Sylvester AJ, Knoblock D, Gillespie E, Amante D, Racine T, McMullan T, Jeong M, Roberts CC, Park YK, Boyer J, et al. Intradermal SynCon® Ebola GP DNA Vaccine is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy Volunteers. The Journal of Infectious Diseases. PMID 30891607 DOI: 10.1093/Infdis/Jiz132 |
0.624 |
|
| 2019 |
Skolnik J, Hahn N, Bellmunt J, Rosencranz S, Diehl M, Morrow M, Kraynyak K, McMullan T. Abstract CT177: INO-5401 + INO-9012 in combination with atezolizumab for locally advanced unresectable or metastatic/recurrent urothelial carcinoma Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-Ct177 |
0.403 |
|
| 2018 |
Patel A, Reuschel EL, Kraynyak KA, Racine T, Park DH, Scott VL, Audet J, Amante D, Wise MC, Keaton AA, Wong G, Villarreal DO, Walters J, Muthumani K, Shedlock DJ, et al. Protective Efficacy and Long-Term Immunogenicity in Cynomolgus Macaques by Ebola Virus Glycoprotein Synthetic DNA Vaccines. The Journal of Infectious Diseases. PMID 30304515 DOI: 10.1093/Infdis/Jiy537 |
0.643 |
|
| 2018 |
Schultheis K, Smith TRF, Kiosses WB, Kraynyak KA, Wong A, Oh J, Broderick KE. Delineating the cell death mechanisms associated with skin electroporation. Human Gene Therapy Methods. PMID 29953259 DOI: 10.1089/Hgtb.2017.105 |
0.378 |
|
| 2018 |
Shore ND, Heath EI, Nordquist LT, Cheng HH, Bhatt K, Morrow M, McMullan T, Kraynyak K, Lee J, Sacchetta B, Liu L, Rosencranz S, Tagawa ST, Parikh RA, Tutrone RF, et al. Evaluation of an immunotherapeutic DNA-vaccine in biochemically relapsed prostate cancer. Journal of Clinical Oncology. 36: 5078-5078. DOI: 10.1200/Jco.2018.36.15_Suppl.5078 |
0.418 |
|
| 2017 |
Morrow MP, Kraynyak K, Sylvester AJ, Dallas M, Knoblock D, Boyer J, Yan J, Vang R, Khan AS, Humeau L, Sardesai NY, Kim JJ, Plotkin S, Weiner D, Trimble CL, et al. Clinical and Immunological Biomarkers for Histologic Regression of High Grade Cervical Dysplasia and Clearance of HPV16 and HPV18 after Immunotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29084917 DOI: 10.1158/1078-0432.Ccr-17-2335 |
0.504 |
|
| 2017 |
Muthumani K, Marnin L, Kudchodkar SB, Perales-Puchalt A, Choi H, Agarwal S, Scott VL, Reuschel EL, Zaidi FI, Duperret EK, Wise MC, Kraynyak KA, Ugen KE, Sardesai NY, Joseph Kim J, et al. Novel prostate cancer immunotherapy with a DNA-encoded anti-prostate-specific membrane antigen monoclonal antibody. Cancer Immunology, Immunotherapy : Cii. PMID 28819703 DOI: 10.1007/S00262-017-2042-7 |
0.528 |
|
| 2017 |
Smith TRF, Schultheis K, Morrow MP, Kraynyak KA, McCoy JR, Yim KC, Muthumani K, Humeau L, Weiner DB, Sardesai NY, Broderick KE. Development of an intradermal DNA vaccine delivery strategy to achieve single-dose immunity against respiratory syncytial virus. Vaccine. PMID 28413132 DOI: 10.1016/J.Vaccine.2017.04.008 |
0.655 |
|
| 2017 |
Walters JN, Ferraro B, Duperret EK, Kraynyak KA, Chu J, Saint-Fleur A, Yan J, Levitsky H, Khan AS, Sardesai NY, Weiner DB. A Novel DNA Vaccine Platform Enhances Neo-antigen-like T Cell Responses against WT1 to Break Tolerance and Induce Anti-tumor Immunity. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 28237837 DOI: 10.1016/J.Ymthe.2017.01.022 |
0.703 |
|
| 2017 |
Shore ND, Heath EI, Nordquist LT, Cheng HH, Bhatt K, Carroll N, Kraynyak K, Lee J, Van Tornout J, Sacchetta B, Tagawa ST, Parikh RA, Tutrone RF, Garcia JA, Whang YE, et al. A clinical trial for the safety and immunogenicity of a DNA-based immunotherapy in men with biochemically (PSA) relapsed prostate cancer. Journal of Clinical Oncology. 35: 80-80. DOI: 10.1200/Jco.2017.35.6_Suppl.80 |
0.409 |
|
| 2017 |
Aggarwal C, Cohen RB, Morrow MP, Kraynyak K, Bauml J, Weinstein GS, Boyer J, Yan J, Mangrolia D, Oyola S, Duff S, Weiner DB, Csiki I, Bagarazzi ML. Immunogenicity results using human papillomavirus (HPV) specific DNA vaccine, INO-3112 (HPV16/HPV18 plasmids + IL-12) in HPV+ head and neck squamous cell carcinoma (HNSCCa). Journal of Clinical Oncology. 35: 6073-6073. DOI: 10.1200/Jco.2017.35.15_Suppl.6073 |
0.587 |
|
| 2017 |
Shore N, Heath E, Nordquist L, Cheng H, Bhatt K, Morrow M, McMullan T, Kraynyak K, Lee J, Sacchetta B, Liu L, Rosencranz S, Tagawa S, Parikh R, Tutrone R, et al. Safety and immunogenicity of a DNA-vaccine immunotherapy in men with biochemically (PSA) relapsed prostate cancer Annals of Oncology. 28: v272. DOI: 10.1093/Annonc/Mdx370.007 |
0.357 |
|
| 2016 |
Muthumani K, Griffin BD, Agarwal S, Kudchodkar SB, Reuschel EL, Choi H, Kraynyak KA, Duperret EK, Keaton AA, Chung C, Kim YK, Booth SA, Racine T, Yan J, Morrow MP, et al. In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine. Npj Vaccines. 1: 16021. PMID 29263859 DOI: 10.1038/npjvaccines.2016.21 |
0.605 |
|
| 2016 |
Morrow MP, Kraynyak KA, Sylvester AJ, Shen X, Amante D, Sakata L, Parker L, Yan J, Boyer J, Roh C, Humeau L, Khan AS, Broderick K, Marcozzi-Pierce K, Giffear M, et al. Augmentation of cellular and humoral immune responses to HPV16 and HPV18 E6 and E7 antigens by VGX-3100. Molecular Therapy Oncolytics. 3: 16025. PMID 28054033 DOI: 10.1038/Mto.2016.25 |
0.628 |
|
| 2016 |
Morrow M, Trimble C, Shen X, Dallas M, Weiner D, Boyer J, Yan J, Kraynyak K, Sylester A, Giffear M, Marcozzi-Pierce K, Shah D, Broderick K, Khan A, Lee J, et al. 505. VGX-3100 Drives Regression of HPV16/18 CIN2/3 and Robust Cellular Immune Responses in Blood and Cervical Tissue in a Blinded, Randomized, Placebo-Controlled Phase 2B Study Molecular Therapy. 24: S201. DOI: 10.1016/S1525-0016(16)33314-7 |
0.588 |
|
| 2016 |
Patel A, Reuschel EL, Kraynyak KA, Racine T, Park DH, Keaton AA, Karuppiah M, Shedlock D, Yan J, Khan A, Tierney K, Sardesai N, Kobinger GP, Weiner DB. 479. An Optimized DNA Vaccine Formulation Protects Against Lethal Ebola Makona Virus Challenge in Non-Human Primates and Elicits Robust Immune Responses Molecular Therapy. 24: S189-S190. DOI: 10.1016/S1525-0016(16)33288-9 |
0.663 |
|
| 2015 |
Trimble CL, Morrow MP, Kraynyak KA, Shen X, Dallas M, Yan J, Edwards L, Parker RL, Denny L, Giffear M, Brown AS, Marcozzi-Pierce K, Shah D, Slager AM, Sylvester AJ, et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet (London, England). PMID 26386540 DOI: 10.1016/S0140-6736(15)00239-1 |
0.59 |
|
| 2015 |
Muthumani K, Falzarano D, Reuschel EL, Tingey C, Flingai S, Villarreal DO, Wise M, Patel A, Izmirly A, Aljuaid A, Seliga AM, Soule G, Morrow M, Kraynyak KA, Khan AS, et al. A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates. Science Translational Medicine. 7: 301ra132. PMID 26290414 DOI: 10.1016/J.Ijid.2016.02.083 |
0.657 |
|
| 2015 |
Kraynyak KA, Bodles-Brakhop A, Bagarazzi M. Tapping the Potential of DNA Delivery with Electroporation for Cancer Immunotherapy. Current Topics in Microbiology and Immunology. PMID 25682101 DOI: 10.1007/82_2015_431 |
0.482 |
|
| 2015 |
Morrow MP, Tebas P, Yan J, Ramirez L, Slager A, Kraynyak K, Diehl M, Shah D, Khan A, Lee J, Boyer J, Kim JJ, Sardesai NY, Weiner DB, Bagarazzi ML. Synthetic consensus HIV-1 DNA induces potent cellular immune responses and synthesis of granzyme B, perforin in HIV infected individuals. Molecular Therapy : the Journal of the American Society of Gene Therapy. 23: 591-601. PMID 25531694 DOI: 10.1038/Mt.2014.245 |
0.421 |
|
| 2015 |
Morrow M, Trimble C, Shen X, Dallas M, Weiner D, Boyer J, Yan J, Kraynyak K, Sylvester A, Giffear M, Marcozzi-Pierce K, Shah D, Broderick K, Khan A, Lee J, et al. Abstract CT131: HPV specific immunotherapy for cervical intraepithelial neoplasia using VGX-3100 induces regression of cervical lesions and potent T-cell responses: Results from a randomized, double-blind, placebo-controlled phase II study Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Ct131 |
0.592 |
|
| 2015 |
Patel A, Reuschel EL, Scott VL, Kraynyak KA, Wong G, Villarreal DO, Karuppiah M, Shedlock D, Yan J, Broderick KE, Khan A, Tierney K, Kobinger GP, Sardesai N, Weiner DB. 450. A Single Immunization With Optimized DNA Vaccines Protects Against Lethal Ebola Virus Challenge in Mice and Induces Seroconversion in Non-Human Primates Following a DNA Prime–DNA Boost Approach Molecular Therapy. 23: S178-S179. DOI: 10.1016/S1525-0016(16)34059-X |
0.697 |
|
| 2015 |
Yan J, Chu JS, Obeng-Adjei N, Morrow MP, Kraynyak K, Slager AM, Yang M, Khan AS, Broderick KE, Sardesai NY, Weiner DB. 417. Induction of Potent Cytotoxic and Antitumor Activity By a Highly Optimized hTERT DNA Vaccine Molecular Therapy. 23: S165. DOI: 10.1016/S1525-0016(16)34026-6 |
0.763 |
|
| 2014 |
Yan J, Tingey C, Lyde R, Gorham TC, Choo DK, Muthumani A, Myles D, Weiner LP, Kraynyak KA, Reuschel EL, Finkel TH, Kim JJ, Sardesai NY, Ugen KE, Muthumani K, et al. Novel and enhanced anti-melanoma DNA vaccine targeting the tyrosinase protein inhibits myeloid-derived suppressor cells and tumor growth in a syngeneic prophylactic and therapeutic murine model. Cancer Gene Therapy. 21: 507-17. PMID 25394503 DOI: 10.1038/Cgt.2014.56 |
0.649 |
|
| 2014 |
Morrow MP, Kraynyak K, Shen X, Knott C, Yan J, Broderick K, Khan A, Giffear M, Lee J, Boyer J, Weiner D, Sardesai N, Bagarazzi M. Boosting of cellular and humoral immune responses to HPV16/18 antigens by VGX-3100: A follow-on phase I trial. Journal of Clinical Oncology. 32: 3101-3101. DOI: 10.1200/Jco.2014.32.15_Suppl.3101 |
0.619 |
|
| 2014 |
Humeau L, Trimble C, Morrow M, Shen X, Dallas M, Weiner D, Boyer J, Yan J, Kraynyak K, Sylvester A, Giffear M, Marcozzi-Pierce K, Shah D, Broderick K, Khan A, et al. DNA vaccine VGX-3100 with electroporation induces regression of cervical intraepithelial neoplasia 2/3 and clears HPV infection with robust T cell responses: results of a randomized, double-blind, placebo-controlled Phase II trial Journal For Immunotherapy of Cancer. 2: 1-1. DOI: 10.1186/2051-1426-2-S3-O17 |
0.604 |
|
| 2012 |
Kathuria N, Kraynyak KA, Carnathan D, Betts M, Weiner DB, Kutzler MA. Generation of antigen-specific immunity following systemic immunization with DNA vaccine encoding CCL25 chemokine immunoadjuvant. Human Vaccines & Immunotherapeutics. 8: 1607-19. PMID 23151454 DOI: 10.4161/Hv.22574 |
0.683 |
|
| 2012 |
Morello CS, Kraynyak KA, Levinson MS, Chen Z, Lee KF, Spector DH. Inactivated HSV-2 in MPL/alum adjuvant provides nearly complete protection against genital infection and shedding following long term challenge and rechallenge. Vaccine. 30: 6541-50. PMID 22947141 DOI: 10.1016/J.Vaccine.2012.08.049 |
0.471 |
|
| 2011 |
Morello CS, Levinson MS, Kraynyak KA, Spector DH. Immunization with herpes simplex virus 2 (HSV-2) genes plus inactivated HSV-2 is highly protective against acute and recurrent HSV-2 disease. Journal of Virology. 85: 3461-72. PMID 21270160 DOI: 10.1128/Jvi.02521-10 |
0.319 |
|
| 2010 |
Kraynyak KA, Kutzler MA, Cisper NJ, Khan AS, Draghia-Akli R, Sardesal NY, Lewis MG, Yan J, Weiner DB. Systemic immunization with CCL27/CTACK modulates immune responses at mucosal sites in mice and macaques. Vaccine. 28: 1942-51. PMID 20188250 DOI: 10.1016/J.Vaccine.2009.10.095 |
0.655 |
|
| 2010 |
Kutzler MA, Kraynyak KA, Nagle SJ, Parkinson RM, Zharikova D, Chattergoon M, Maguire H, Muthumani K, Ugen K, Weiner DB. Plasmids encoding the mucosal chemokines CCL27 and CCL28 are effective adjuvants in eliciting antigen-specific immunity in vivo. Gene Therapy. 17: 72-82. PMID 19847203 DOI: 10.1038/Gt.2009.112 |
0.767 |
|
| 2009 |
Kraynyak KA, Kutzler MA, Cisper NJ, Laddy DJ, Morrow MP, Waldmann TA, Weiner DB. Plasmid-encoded interleukin-15 receptor alpha enhances specific immune responses induced by a DNA vaccine in vivo. Human Gene Therapy. 20: 1143-56. PMID 19530914 DOI: 10.1089/Hum.2009.025 |
0.739 |
|
| 2009 |
Kraynyak KA, Kutzler MA, Pahar B, Sylvester A, Yan J, Carnathan D, Khan AS, Sardesai N, Moldoveanu Z, Mestecky J, Betts MR, Marx P, Weiner DB. P19-46. Co-delivery of mucosal chemokine plasmids in a systemically delivered DNA vaccine elicits systemic and mucosal immune responses in mice and macaques Retrovirology. 6: P366. DOI: 10.1186/1742-4690-6-S3-P366 |
0.661 |
|
| Show low-probability matches. |